Asthma
Asthma is a chronic inflammatory disease of the lungs characterized by episodes of wheezing, coughing, chest tightness, and shortness of breath, with symptoms that can be triggered by factors such as allergens, cold air, and exercise. Its symptoms are variable, recurring, and can often become worse at night or with physical activity.
Health Outcomes
- Absence of Severe Adverse Reactions
- Absence of Treatment-Related Side Effects
- Accelerated Immune Response Maturation
- Accelerated Oral Tolerance Development
- Altered Chemokine Response
- Altered Expression of Immune Products
- Altered IFN-γ Levels
- Altered IL-4 Levels
- Altered Microbial Composition
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Serum IL-6 Levels
- Altered TH1/TH2 Immune Response
- Beneficial Clinical Effects
- Confirmed Safety of Treatment
- Decreased IFN-γ Levels
- Decreased Interferon-Gamma Level
- Decreased Lower Respiratory Quotient
- Decreased Oxygen Saturation
- Demonstrated Long-term Safety
- Elevated Blood Cytokine Levels
- Elevated IL-10 Levels
- Elevated IL-22 Levels
- Elevated Interleukin-10 Levels
- Elevated Interleukin-17 Levels
- Elevated Interleukin-8 Levels
- Elevated Serum IL-2 Levels
- Elevated Serum IgE Levels
- Elevated Serum Immunoglobulin Levels
- Elevated Serum Substance P Levels
- Elevated Serum Total Ig Levels
- Elevated TNF-α Expression Level
- Elevated Type I IFN Expression in Lung Lymphocytes
- Enhanced Anti-inflammatory Properties
- Enhanced Anti-inflammatory Response
- Enhanced Cytokine Production
- Enhanced Cytokine Response
- Enhanced Goblet Cell Function
- Enhanced Immune Response (Higher IL-4 Levels)
- Enhanced Infant Gut Microbiota by Bifidobacterium lactis
- Enhanced Inflammation Resolution
- Enhanced Influenza Resistance
- Enhanced Interleukin-10 Production
- Enhanced Leukocyte Recruitment
- Enhanced Mucosal Immune Function
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Protection Against Influenza Infection
- Enhanced Resistance to Respiratory Infections
- Enhanced Type 2 Helper T Cell Response
- Improved Adherence Ability
- Improved Airway Allergic Inflammation
- Improved Airway Immune Response
- Improved Airway Mucosa Condition
- Improved Airway Secretion Clearance
- Improved Allergic Immune Responses
- Improved Allergic Inflammation Markers
- Improved Allergic Outcomes
- Improved Anti-Allergy-Related Cytokine Profile
- Improved Antiallergic Function
- Improved Asthmatic Condition
- Improved Atopic Dermatitis
- Improved Atopic Dermatitis Symptoms
- Improved Atopic Eczema
- Improved Clinical Disease Activity
- Improved Consumer Acceptance
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Deep Lung Delivery Feasibility
- Improved Disease Management
- Improved Efficacy Rate
- Improved Endurance Performance
- Improved Environmental Stress Tolerance
- Improved Exercise-Induced Bronchoconstriction Lung Function
- Improved FEV1
- Improved Forced Vital Capacity
- Improved Global Assessment
- Improved Health Outcomes
- Improved Health Status
- Improved Health Status Score
- Improved Health in Children with Allergies
- Improved Histopathological Findings in Lungs
- Improved Human Health
- Improved Immune Balance
- Improved Immune Modulation
- Improved Immune Parameters
- Improved Immune Tolerance
- Improved Immunity Status
- Improved Immunoglobulin A Production
- Improved Immunoglobulin Levels
- Improved Immunoinflammatory Markers
- Improved Inflammation Homeostasis
- Improved Inflammation Levels
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Influenza Infection Control
- Improved Interleukin-4 Levels
- Improved JMCIS Score
- Improved Leukocyte Recruitment
- Improved Lung Barrier Function
- Improved Lung Function
- Improved Medication Adherence
- Improved Overall Symptom Score
- Improved Oxygenation Index
- Improved Perceived Recovery
- Improved Physiological Parameters
- Improved Proportion of Healthy Days
- Improved Pulmonary Function
- Improved Resistance to Pneumococcal Respiratory Infection
- Improved Respiratory Humoral Response
- Improved Respiratory Immune Function
- Improved Respiratory Immunity
- Improved Respiratory Innate Immune Response
- Improved Respiratory Mucosal Barrier Function
- Improved Respiratory Tract Health
- Improved Responder Rate
- Improved Response
- Improved Survival Rate Against Influenza Virus
- Improved Swimming Performance
- Improved Symptom Control
- Improved Symptoms
- Improved Th1/Th2 Balance
- Improved Treatment Efficacy
- Improved VO2 Max
- Improved Various Elements
- Improved Yo-Yo Test Performance
- Increased Abundance of Goblet Cells
- Increased Acceptability of Use
- Increased Anti-Inflammatory Cytokine IL-10
- Increased Anti-Inflammatory Levels
- Increased Anti-Viral Factor Expression in Lung
- Increased Anti-inflammatory Cytokines
- Increased Anti-inflammatory to Pro-inflammatory Cytokine Ratio
- Increased Antibody Secretion to Beta-Lactoglobulin
- Increased Antigen-Specific IgG1 Levels
- Increased Bacillus Spore Counts
- Increased CCL-20 Levels
- Increased CD163+ Macrophage Density
- Increased Cytokine Production
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Secretion
- Increased Dendritic Cell Activation
- Increased Endogenous Acrolein Formation
- Increased Eosinophil Count
- Increased Epithelial-Derived IgG Levels
- Increased Exercise Endurance
- Increased Goblet Cell Count
- Increased Goblet Cell Differentiation
- Increased Histamine Production
- Increased Hospital Admissions
- Increased IFN-γ Concentration
- Increased IFN-γ to IL-4 Ratio
- Increased IL-10 Levels
- Increased IL-17 Levels
- Increased IL-2 Secretion
- Increased IL-6 Levels in Early Phase
- Increased Immune Cell Presence
- Increased Immune Marker Activation
- Increased Immunoglobulin A (IgA)-Positive Cells
- Increased Immunoglobulin G1 Levels
- Increased Immunoglobulin Levels
- Increased Inflammatory Cytokines
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Interleukin 8 Levels
- Increased Interleukin-10 Production
- Increased Lung CD3+CD4+ IFN-γ+ T Cells
- Increased Lymphoid Cell Proliferation in Germ-Free Animals
- Increased Mast Cells in Mucosal Tissues
- Increased Mucin Production
- Increased Mucin Secretion
- Increased Mucosal B-Cell Responses
- Increased Mucus Binding Capacity
- Increased Mucus Secretion
- Increased Nerve Growth Factor Level
- Increased Nitric Oxide Level
- Increased Nitric Oxide Secretion
- Increased OVA-specific IgG Levels Upon Immunization
- Increased Presence of Bifidobacterium lactis
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Production of Anti-inflammatory Cytokine IL-10
- Increased Production of Anti-inflammatory Histamine
- Increased Regulatory T Cell Response
- Increased Respiratory Burst Activity
- Increased Respiratory Sensitization
- Increased Salivary IgA Levels
- Increased Secretory IgA Level
- Increased Secretory Immunoglobulin A
- Increased Serum IL-10 Levels
- Increased Serum Macrophage Inflammatory Protein-1β Levels
- Increased Serum Metabolites to Combat Inflammation
- Increased Skin Mucus Protein Levels
- Increased Sulfite Tolerance
- Increased TIMP-1 Levels
- Increased Th17 Polarization
- Increased Th2 Cytokines Production
- Increased Time to Exhaustion
- Increased Transforming Growth Factor-β Levels
- Inflammatory Disease Protection
- Long-Lasting Immunomodulatory Effects After Weaning
- Maintained Clinical Safety Parameters
- Maintained Mucosa-Associated Immunity
- Managed Cystic Fibrosis
- Modulated Cytokine Levels
- Modulated Eicosanoid Levels
- Modulated Host Immune Response
- Modulated Immune System
- Modulated Immunoinflammatory Parameters
- Modulated Immunological Profile
- Modulated Inflammatory Cytokine Levels
- Modulated Inflammatory Response
- Modulated Pulmonary Innate Immune Microenvironment
- Modulated Systemic Immune Response
- Modulated Systemic Th1/Th2 Balance
- Modulation of Pulmonary Innate Immune Function
- No Adverse Safety Findings
- No Change in Anthropometric Parameters
- No Change in Anxiety
- No Change in Cytokines or Chemokines Levels
- No Change in Inflammation Markers
- No Change in Inflammatory Cytokines
- No Clear Clinical Benefit
- No Effect on Growth Parameters
- No Improvement in Allergy Symptoms
- No Improvement in Birch-Pollen Allergy Symptoms
- No Influence on Oropharyngeal Microbiota
- No Meaningful Change in IL-8
- No Mutagenicity, Teratogenicity, or Genotoxicity
- No Reduction in Atopic Dermatitis Severity
- No Significant Change in Blood Indices
- No Significant Change in IgE Levels
- No Significant Change in Inflammatory Responses
- No Significant Reduction in Atopic Dermatitis Severity
- No Significant Weight Change
- Prevented Allergic Reactions
- Prevention of Aberrant Inflammatory Response
- Prevention of Mucus Barrier Decline
- Protection Against Impact of IoNPs
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced Abundance of Pro-inflammatory Bacteria
- Reduced Activation of CD63 Expressing Basophils
- Reduced Aggravation of Chronic Inflammation
- Reduced Airway Hyperresponsiveness
- Reduced Airway Inflammation
- Reduced Airway Inflammation Score
- Reduced Airway Pathological Responses
- Reduced Airway Remodeling
- Reduced Airway T Helper Type 2 Cytokines
- Reduced Allergen Hyperreactivity
- Reduced Allergic Diseases
- Reduced Allergic Disorders
- Reduced Allergic Inflammatory Response
- Reduced Allergic Lung Inflammation
- Reduced Allergic Markers
- Reduced Allergic Reaction Risk
- Reduced Allergic Reactions
- Reduced Allergic Responses
- Reduced Allergic Scores
- Reduced Allergic Symptoms
- Reduced Anaphylactic Shock Symptoms
- Reduced Antigen-Specific IgE Levels
- Reduced Asthma Exacerbation
- Reduced Asthma Exacerbations
- Reduced Asthma Medication Use
- Reduced Asthma Severity
- Reduced Asthma Symptom
- Reduced Atopic Diseases
- Reduced Baseline IL-8 Secretion
- Reduced Bifidobacterium Counts
- Reduced Chemokine Production
- Reduced Chronic Obstructive Pulmonary Disease Onset Risk
- Reduced Common Cold Incidence in Susceptible Populations
- Reduced Concomitant Medication Usage
- Reduced Corticosteroid Usage
- Reduced Day School Absenteeism
- Reduced Disease Activity
- Reduced Disease Symptoms
- Reduced Disruption of Normal Activities Due to Allergies
- Reduced Egg Allergy
- Reduced Egg White Sensitization
- Reduced Eosinophil Count
- Reduced Eosinophil Infiltration
- Reduced Eosinophil Peroxidase Levels
- Reduced Eosinophilic Inflammation
- Reduced Eosinophils in Bronchoalveolar Lavage Fluid
- Reduced Episode Frequency
- Reduced Epithelial Barrier Disruption
- Reduced Exposure to Harmful Substances
- Reduced Expression of Inflammation-Related Genes
- Reduced Expression of Pro-Inflammatory Cytokines in Lung
- Reduced Expression of Proinflammatory Mediators
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced HDM-Specific IgG1 Levels
- Reduced Healthcare Costs
- Reduced Histamine Release
- Reduced Hospital Length of Stay
- Reduced Hospitalisation
- Reduced Hospitalization Duration
- Reduced Hospitalization Rate
- Reduced Hypersensitivity Responses
- Reduced Hypoxia
- Reduced IL-17 Production in Splenocytes
- Reduced IL-1β Levels
- Reduced IL-4 Levels
- Reduced IL-4 Secretion
- Reduced IL-4 Secretion from Naïve T Cells
- Reduced IL-5 Levels
- Reduced IL-6 Production
- Reduced IL-8 Production
- Reduced IL-8 Secretion
- Reduced IL-9 Levels
- Reduced IgE Levels
- Reduced IgE Production
- Reduced Immunoglobulin E Production
- Reduced Immunoinflammatory Markers
- Reduced Impact of Rhinovirus Infection
- Reduced Incidence of Allergic Disorders
- Reduced Incidence of Allergic Manifestations
- Reduced Incidence of Influenza
- Reduced Incidence of Milk Allergy
- Reduced Incidence of Respiratory Illness
- Reduced Infant Allergies
- Reduced Infant Atopic Eczema and Allergic Disease
- Reduced Infant Wheeze
- Reduced Inflammation
- Reduced Inflammation Levels
- Reduced Inflammation Markers
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammation in the Lower Respiratory Tract
- Reduced Inflammatory Activities
- Reduced Inflammatory Biomarker Level
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Diseases
- Reduced Inflammatory Effects
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Injury
- Reduced Inflammatory Markers
- Reduced Inflammatory Mediators
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Response
- Reduced Inflammatory Status
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Tone
- Reduced Interleukin Level
- Reduced Interleukin-10 Levels
- Reduced Interleukin-12 Level
- Reduced Interleukin-17 Level
- Reduced Interleukin-4 Levels
- Reduced Interleukin-4 Production
- Reduced LPS-Induced Inflammation
- Reduced Length of Stay
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Lifetime Prevalence of Atopic Sensitization
- Reduced Lifetime Prevalence of Wheeze
- Reduced Local Immunoglobulin Production
- Reduced Lung Damage
- Reduced Lung Histopathology Scores
- Reduced Lung Inflammation
- Reduced Lung Injury
- Reduced Lung Neutrophils
- Reduced Lung Tissue Damage
- Reduced MAPK Activation
- Reduced Mechanical Ventilation Duration
- Reduced Medication Use for Allergies
- Reduced Mold Presence
- Reduced Morbidity Rate
- Reduced Mortality from Influenza Infection
- Reduced Mucosal Inflammation
- Reduced Mucus Secretion
- Reduced NF-kappaB Nuclear Translocation
- Reduced NSAID Consumption
- Reduced Neutrophil Recruitment
- Reduced Non-Programmed Medical Visits
- Reduced OVA-Specific Antibodies
- Reduced Occurrence of Pasty Vent
- Reduced Ovalbumin-Specific IgE Level
- Reduced Ovalbumin-Specific IgE Production
- Reduced Overall Symptom Score
- Reduced PICU Discharge Time
- Reduced Pathological Symptoms
- Reduced Pediatric Exacerbations
- Reduced Pediatric Intensive Care Unit Stay
- Reduced Phospho-p65 Translocation
- Reduced Physical Symptoms
- Reduced Prevalence of Atopic Sensitization
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Fatty Acids
- Reduced Pro-Inflammatory Mediator Production
- Reduced Pro-inflammatory Biomarker Level
- Reduced Pro-inflammatory Cytokine Interleukin-8 Levels
- Reduced Pro-inflammatory Cytokine Levels
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Immune Responses
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokine Secretion
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factor Levels
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Proinflammatory Signaling
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Proportion of Pathogenic Genus
- Reduced Pulmonary Free-CML
- Reduced Pulmonary Inflammation
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Respiratory Illness
- Reduced Respiratory Inflammation Severity
- Reduced Respiratory Symptom Days
- Reduced Respiratory Symptoms
- Reduced Risk of COVID-19 Progression
- Reduced Risk of Colorectal Cancer
- Reduced Risk of Multiple Sclerosis
- Reduced Risk of Sensitization in Infants
- Reduced Risk of Upper Respiratory Tract Infections
- Reduced School Absence Days
- Reduced Serum Chemokine Levels
- Reduced Serum IL-4 Levels
- Reduced Serum IL-6 Levels
- Reduced Serum IgE Levels
- Reduced Serum Immunoglobulin E Levels
- Reduced Serum Inflammatory Cytokines
- Reduced Serum Interferon Gamma
- Reduced Serum OVA-specific IgE Levels
- Reduced Serum OVA-specific IgG1 Levels
- Reduced Severity of Acute Respiratory Infection
- Reduced Severity of Allergic Rhinitis Symptoms
- Reduced Severity of Influenza Infection
- Reduced Severity of Lung Injuries
- Reduced Severity of Symptoms Per Day
- Reduced Standard Care Medication Need
- Reduced Steroid Load
- Reduced Steroid Usage
- Reduced Susceptibility to Inflammatory Exposure
- Reduced Swimming Time
- Reduced Symptom Severity Scale Score
- Reduced Symptoms
- Reduced Systemic Anaphylaxis
- Reduced Th-2 Cytokine Concentrations
- Reduced Th1/Th2 Ratio
- Reduced Th1/Th2 Ratio (IFN-γ/IL-4)
- Reduced Th17 Cell Level
- Reduced Th2 Cytokine Levels
- Reduced Th2 Cytokine Production
- Reduced Th2 Immunity
- Reduced Th2 Reactions
- Reduced Th2 Response
- Reduced Total Cells in Bronchoalveolar Lavage Fluid
- Reduced Total IgE Levels
- Reduced Total Symptom Score
- Reduced Type 2 Immune Responses
- Reduced Type-2-helper-T-cell-dominant Inflammation
- Reduced Upper Respiratory Infections
- Reduced Use of Rescue Medication
- Reduced Wheeze
- Reduced Wheeze Prevalence
- Reduced Wheezing
- Reduced γ-Proteobacteria Levels in Human Milk-Fed Infants
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Inflammatory Responses
- Regulated Interleukin 8 Levels
- Restored Goblet Cell Function
- Restored Th1/Th2 Cytokine Balance
- Safe Drug Administration
- Stable Immune System Responses
- Stimulation of Immune Cells
- Symptom Alleviation
- Unchanged Apple-Induced Symptoms
- Unchanged IFN-γ Levels
- Unchanged Immune Parameters
- Upregulated Macrophage Inhibitory Factor
- Well-Tolerated Long-Term Use